Brand drug lobbyists are worried the president's plan to lower drug costs, which will be announced Friday, might include a measure to set prices at levels paid in other countries. Lobbyists have no advance notice of what the plan entails beyond what's publicly available, but they are spooked by the combination of two developments: the White House Council of Economic Advisers identified an international reference pricing scheme in a February report and the president and his health secretary keep complaining...